InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s disease and ocular and dermatological indications.